Brought to you by 
Voyager Therapeutics closes $45mm Series A financing
04 Mar 2014
Executive Summary
Third Rock Ventures launched Voyager Therapeutics Inc. and provided the start-up with $45mm in Series A financing to support work, over at least the next three years, on gene therapeutics for fatal CNS diseases. Third Rock, which has incubated Voyager for the last couple years, says it would be willing to add another VC, including a corporate backer, to later tranches.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Synthesis Technologies, Production Processes
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Voyager Therapeutics closes $45mm Series A financing
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice